<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00992576</url>
  </required_header>
  <id_info>
    <org_study_id>2008-005312-18</org_study_id>
    <nct_id>NCT00992576</nct_id>
  </id_info>
  <brief_title>Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain</brief_title>
  <acronym>HMX3501</acronym>
  <official_title>A Confirmatory, Placebo-controlled, Randomised, Double-blind, Single-dummy, Parallel Group, Ratio-finding Study in Constipated Pain Patients to Establish an Optimal Hydromorphone - Naloxone Ratio With an Improved Bowel Function and a Comparable Analgesic Efficacy Compared to Hydromorphone Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mundipharma Research GmbH &amp; Co KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mundipharma Research GmbH &amp; Co KG</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish an optimal hydromorphone - naloxone ratio with an
      improved bowel function for constipated pain patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects suffering from cancer or non-cancer pain suffering from constipation cased or
      aggravated by opioids will be randomised to one of four ratios of hydromorphone PR plus
      naloxone PR or Hydromorphone PR plus placebo to investigate whether a hydromorphone/naloxone
      combination will lead to comparable analgesia, with a decrease in constipation, and to
      investigate the optimal dose ratio of hydromorphone and naloxone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bowel Function Measure Average pain scores</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bowel Function Measures Rescue medication use</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Constipation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Hydromorphone PR + Active Naloxone PR</intervention_name>
    <description>Optimal pain relief and improved bowel function in constipated pain patients</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Hydromorphone PR + Placebo Naloxone PR</intervention_name>
    <description>Optimal pain relief and improved bowel function in constipated pain patients</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects at least 18 years with a history of non-cancer or cancer pain
             that requires around-the-clock opioid therapy (8, 24 or 48 mg hydromorphone PR per day
             for the duration of the study).

          2. Subjects with constipation caused or aggravated by opioids

          3. Subjects must be willing to discontinue their current opioid analgesic routine, and .

          4. current laxative regimen

        Exclusion Criteria:

          1. Chronic or intermittent pain that results from Fibromyalgia or Rheumatoid Arthritis.

          2. Subjects presently taking, or who have taken, naloxone &lt;=30 days prior to the start of
             the Screening Period.

          3. Subjects suffering from diarrhoea.

          4. Abnormal liver or kidney function.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hunter New England Area Health Service</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2300</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien - Universitätskliniken</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasme Hospital</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poradna pro lecbu bolesti</name>
      <address>
        <city>Pribram</city>
        <zip>261-01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Speciallæge Michael Crawford</name>
      <address>
        <city>København K.</city>
        <zip>1100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oma Lääkäri Oy</name>
      <address>
        <city>Kuopio</city>
        <zip>Fl-70100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital Amiens Nord</name>
      <address>
        <city>Amiens Cedex 1</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel-Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis, locatie Zeist</name>
      <address>
        <city>Zeist</city>
        <zip>3707HL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki w Krakowie Zakład Badania</name>
      <address>
        <city>Krakow</city>
        <zip>31-531</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Cluj</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avondale Surgery</name>
      <address>
        <city>Chesterfield</city>
        <zip>S40 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2009</study_first_submitted>
  <study_first_submitted_qc>October 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2009</study_first_posted>
  <last_update_submitted>February 14, 2012</last_update_submitted>
  <last_update_submitted_qc>February 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2012</last_update_posted>
  <keyword>Confirmatory</keyword>
  <keyword>Constipation</keyword>
  <keyword>Pain</keyword>
  <keyword>Hydromorphone</keyword>
  <keyword>Naloxone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Hydromorphone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

